ReviewCells2019
HCC-Derived Exosomes: Critical Player and Target for Cancer Immune Escape.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 116 citations in OpenAlex.
- Molecular Pathophysiology of Hepatocellular Carcinoma: From Metabolic Inflammation to Therapeutic Targets.Cancers · 2026Review
- Review
- Roles of Extracellular Vesicle-Derived microRNAs in Metabolic Dysfunction-Associated Steatotic Liver Disease to Hepatocellular Carcinoma.Biomedicines · 2026Review
- Cholangiocarcinoma derived exosomes attenuate the anti-tumor functions of NK cells.Scientific reports · 2026Article
- Lipopolysaccharide-induced M1-type Macrophages Enhance T Cell Activity and Promote the Apoptosis of Hepatocellular Carcinoma Cells.Current topics in medicinal chemistry · 2026Article
- Systematic pan-cancer analysis of IL3RA carcinogenesis in human tumors, combined with bioinformatics analysis.Discover oncology · 2025Article
- Long non-coding RNA NR2F1-AS1: an increasingly significant LncRNA in human cancers.Journal of physiology and biochemistry · 2025Review
- Potential Roles of Serum Exosomal CD155 and its Impact on NK Cell Immunosuppression in Hepatocellular Carcinoma.Balkan medical journal · 2025Article
- Exosomal crosstalk: the metastatic language of hepatocellular carcinoma.Frontiers in immunology · 2025Review
- Targeting cancer via macrophage-derived exosomal miRNAs: implications for tumor progression and resistance.Frontiers in immunology · 2025Review
- The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.Korean journal of clinical oncology · 2024Review
- Mechanisms of Tolerance Induction in Liver Transplantation: Lessons Learned from Fetomaternal Tolerance, Autoimmunity and Tumor Immunity.International journal of molecular sciences · 2024Review
- Decoding the spatiotemporal heterogeneity of tumor-associated macrophages.Molecular cancer · 2024Review
- Extracellular vesicles as potential biomarkers for diagnosis and recurrence detection of hepatocellular carcinoma.Scientific reports · 2024Article
- Knockdown of liver cancer cell-secreted exosomal PSMA5 controls macrophage polarization to restrain cancer progression by blocking JAK2/STAT3 signaling.Immunity, inflammation and disease · 2024Article
- MicroRNAs in Hepatocellular Carcinoma: Insights into Regulatory Mechanisms, Clinical Significance, and Therapeutic Potential.Cancer management and research · 2024Review
- Insights about exosomal circular RNAs as novel biomarkers and therapeutic targets for hepatocellular carcinoma.Frontiers in pharmacology · 2024Review
- Research progress on the role of adipocyte exosomes in cancer progression.Oncology research · 2024Review
- Exosome-Related FTCD Facilitates M1 Macrophage Polarization and Impacts the Prognosis of Hepatocellular Carcinoma.Biomolecules · 2023Article
- Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications.Cancers · 2023Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, and currently the second most common cause of cancer-related deaths worldwide with increasing incidence and poor prognosis. Exosomes are now considered as important mediators of host anti-tumor immune response as well as tumor cell immune escape. HCC-derived exosomes have been shown to attenuate the cytotoxicity of T-cells and NK cells, and promote the immuno-suppressive M2 macrophages, N2 neutrophils, and Bregs. These exosomes harbor several immune-related non-coding RNAs and proteins that drive immune-escape and tumor progression, and thus may serve as potential diagnostic biomarkers and therapeutic targets for HCC. In a previous study, we identified miR146a as an exosomal factor that promotes M2-polarization and suppresses the anti-HCC function of T-cells. In this review, we summarized the role of tumor-derived exosomes and their key components in mediating tumor immune escape during HCC development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.